大禹金融(01073)发布公告，公司建议以供股方式，按于记录日期每持有2股现有股份获发1股供股股份 的基准，以每股供股股份0.12港元的认购价，向合资格股东发行最多11.39亿股供股股份(假设已发行股 份数目于记录日期或之前概无变动)，借此筹集最多约1.367亿港元(扣除开支前)。 供股的最高所得款项净额估计约为1.361亿港元(假设已发行股份数目于记录日期或之前概无变动)。公司 拟将供股所得款项净额中的约1.161亿港元用于集团的保证金融资业务及2000万港元用作集团的一般营 运资金。 ...

智通财经APP讯，大禹金融(01073)发布公告，公司建议以供股方式，按于记录日期每持有2股现有股份 获发1股供股股份的基准，以每股供股股份0.12港元的认购价，向合资格股东发行最多11.39亿股供股股 份(假设已发行股份数目于记录日期或之前概无变动)，借此筹集最多约1.367亿港元(扣除开支前)。 供股的最高所得款项净额估计约为1.361亿港元(假设已发行股份数目于记录日期或之前概无变动)。公司 拟将供股所得款项净额中的约1.161亿港元用于集团的保证金融资业务及2000万港元用作集团的一般营 运资金。 ...

供股的最高所得款项净额（经扣除相关开支后）估计约为1.36亿港元。公司拟将供股所得款项净额中的 约1.16亿港元用于集团的保证金融资业务及2000万港元用作集团的一般营运资金。 格隆汇7月30日丨大禹金融(01073.HK)发布公告，公司建议以供股方式，按每持有两(2)股现有股份获发 一(1)股供股股份的基准，以每股供股股份0.12港元的认购价，向合资格股东发行最多11.4亿股供股股 份，藉此筹集最多约1.37亿港元（扣除开支前）。 ...

根据上述有效接纳及申请的结果，补偿安排所涉及的未获认购股份及不合资格股东未售股份总数将为 6226万股供股股份。 新明中国(02699)发布公告，于2025年7月8日(星期二)下午四时正(即接纳最后时限)，已接获合共8份有效 申请，涉及合共1288.49万股供股股份，相当于供股项下所提呈发售供股股份总数约17.15%。 董事会谨此宣布，于2025年7月21日(星期一)下午四时正(即配售事项结束日期)，已成功根据配售事项向 不少于6名承配人配售6226万股未获认购股份，配售价为每股1.12港元，相等于认购价。因此，概无根 据配售事项可分派予不行动股东及不合资格股东的净收益。 ...

Core Viewpoint - The company successfully completed a rights issue, raising approximately HKD 40.5 million, with net proceeds of about HKD 39.5 million intended for debt repayment, operational expenses, and marketing costs [1][2]. Group 1: Rights Issue Details - The rights issue was conducted on a basis of 1 new share for every 2 existing shares held, with a total of 197,547,320 shares accepted, representing about 53.67% of the total offered shares [1]. - A total of 170,524,045 shares, which were not subscribed, were successfully placed at a price of HKD 0.11 per share [1]. - The total number of shares to be issued and allocated from the rights issue is 368,071,365, which is 100% of the total offered shares [1]. Group 2: Changes in Shareholding Structure - Following the rights issue, the shareholding of Yongrong (Hong Kong) Asset Management Co., Ltd. decreased from 18.60% to 12.40% [2]. - Li Wei's shareholding reduced from 4.18% to 2.79%, while independent subscribers now hold 170,524,045 shares, accounting for 15.44% [2]. - The proportion of other public shareholders decreased from 77.22% to 69.37% [2]. Group 3: Timeline and Distribution - The payment for the rights shares is expected to be mailed by July 9, 2025, and trading of the rights shares is anticipated to commence on July 10, 2025 [2].

Core Viewpoint - Morgan Stanley reports that Henderson Land Development (00012) plans to issue HKD 8 billion convertible bonds (CB), which is somewhat unexpected given the recent strong performance of its stock, as issuing CBs is not common for Hong Kong real estate companies [1] Group 1: Company Actions - The issuance of CBs is seen as a low-cost financing option with a coupon rate of 0.5%, potentially encouraging other developers to explore similar financing methods to lower their average cost of capital [1] - New World Development (00017) is identified as the company with the highest likelihood of a rights issue within the research scope [1] Group 2: Market Performance - Since mid-June, Hong Kong real estate stocks have outperformed the Hang Seng Index by 8% [1] - The recent CB issuance, along with rising Hong Kong Interbank Offered Rate (HIBOR), may trigger short-term profit-taking, particularly in Henderson Land [1] Group 3: Investment Recommendations - Morgan Stanley suggests buying stocks with clear catalysts, such as Swire Properties (01972) due to share buybacks and improvements in the Chinese retail sector, and Link REIT (00823) due to its inclusion in the Stock Connect and capital recycling [1] - For Henderson Land, after the market digests potentially weak performance in the first half of 2025 (with a projected 46% year-on-year decline in net profit due to a one-off project in the first half of 2024), the recommendation is to "buy" [1] - From a tactical perspective, Morgan Stanley sees upside potential in Wharf Real Estate Investment Company (01997), which has been upgraded to "overweight" due to a strengthening trend in retail sales [1]

Core Viewpoint - ALCO HOLDINGS (00328.HK) announced a proposed capital reorganization involving share consolidation, capital reduction, and share split to improve its capital structure and address accumulated losses [1][2] Group 1: Share Consolidation - The company plans to consolidate every ten (10) existing shares with a par value of HKD 0.01 into one (1) share with a par value of HKD 0.10 [1] - Any fractional shares resulting from the consolidation will be cancelled [1] Group 2: Capital Reduction - The capital reduction will involve the cancellation of any fractional shares resulting from the consolidation and adjusting the total number of issued shares to the nearest whole number [2] - The par value of each issued consolidated share will be reduced from HKD 0.10 to HKD 0.01 [2] Group 3: Share Split - Following the capital reduction, each unissued consolidated share with a par value of HKD 0.10 will be split into ten (10) shares with a par value of HKD 0.01 [1] Group 4: Share Premium Reduction - The total amount in the share premium account will be reduced to zero, and the resulting amounts will be transferred to the company's paid surplus account to offset accumulated losses [2] Group 5: Rights Issue - After the capital reorganization, the company proposes a rights issue where each adjusted share will entitle the holder to four (4) new shares at a subscription price of HKD 3.24 per share [2] - The rights issue aims to raise up to approximately HKD 148.465 million before expenses through the issuance of up to 45,822,744 new shares [2]

Core Viewpoint - China Health Group (00673) announced a subscription and rights issue to address financial challenges and capital needs for ongoing operations and future development [1][2] Group 1: Subscription Agreements - The company entered into Subscription Agreements A, B, and C on April 30, 2025, to issue a total of 700 million new shares at a subscription price of HKD 0.1 per share [1] - The subscription price represents a discount of approximately 28.6% compared to the closing price of HKD 0.140 per share on April 30 [1] - The total number of subscription shares represents about 142.4% of the existing shares as of the announcement date and approximately 52.3% of the expanded share capital post-issue [1] Group 2: Rights Issue Details - The company proposes a rights issue based on a ratio of 3 new shares for every 10 shares held at a price of HKD 0.1 per share, aiming to raise between approximately HKD 14.7 million and HKD 15 million [2] - The estimated gross proceeds from the subscription and rights issue are approximately HKD 84.7 million, with net proceeds expected to be around HKD 80.9 million [2] Group 3: Use of Proceeds - The net proceeds from the subscription and rights issue are planned to be used as follows: approximately HKD 65.3 million for settling payables, including HKD 31.2 million for judgment debts, HKD 15.5 million for loans, HKD 3.6 million for overdue employee salaries, HKD 5.1 million for overdue professional fees, and HKD 9.9 million for overdue director remuneration [2] - The remaining balance of approximately HKD 15.6 million will be allocated for the company's working capital [2] Group 4: Resumption of Trading - Following the announcement, the company has applied to resume trading of its shares starting from 9:00 AM on May 23, 2025 [2]

Core Viewpoint - The company is implementing a series of financial restructuring measures including share consolidation, debt capitalization, and a rights issue to improve its financial position and comply with listing rules [1][2][3] Group 1: Share Consolidation and Capital Structure - The board proposes to consolidate every 20 existing shares with a par value of HKD 0.00004 into 1 share with a par value of HKD 0.0008 [1] - After the consolidation, the company's legal capital will remain HKD 1 billion, divided into 125 billion consolidated shares, with 641 million shares issued [1] - The trading unit will change from 8,000 existing shares to 16,000 consolidated shares [1] Group 2: Debt Capitalization Agreements - The company has entered into two debt capitalization agreements, agreeing to issue 289.6 million shares to Subscriber I and 215 million shares to Subscriber II at a capitalization price of HKD 0.20 per share [2] - The total amount of the capitalization issuance is approximately HKD 10.09 million, which will offset the company's debts to the subscribers [2] - Post-capitalization, the capitalized shares will represent about 78.7% of the issued share capital after consolidation [2] Group 3: Rights Issue - Following the completion of debt capitalization, the company plans to issue 573 million rights shares at a price of HKD 0.20 per share, aiming to raise up to approximately HKD 114.6 million [3] - The net proceeds from the rights issue are estimated to be around HKD 112 million after expenses [3]

(ii)股本削减，据此因股份合并而产生之公司已发行股本中的任何零碎合并股份将予以注销，及透过以 每股已发行合并股份1.99港元为限注销实缴股本，将每股已发行合并股份的面值由2.00港元削减至0.01 港元; (iii)股份分拆，据此紧随股本削减后，每股面值2.00港元的法定但未发行合并股份(包括因股本削减而产 生的法定但未发行合并股份)分拆为200股每股面值0.01港元的经调整股份; (iv)因股本削减而产生的进账将用于抵销公司于股本重组生效日期的累计亏损，从而减少公司的累计亏 损，进账余额(如有)将计入公司的实缴盈余账及按所有适用法例及公司细则所准许的方式由公司动用。 董事会建议待股本重组生效后，将在联交所买卖的每手买卖单位由2万股现有股份改为5000股经调整股 份。 智通财经APP讯，资本界金控(00204)发布公告，董事会建议按以下方式进行股本重组： (i)股份合并，据此每20股已发行及未发行每股面值0.10港元的现有股份将合并为1股每股面值2.00港元的 合并股份; 董事会建议，待股本重组生效后，按于记录日期每持有1股经调整股份获配发3股供股股份的基准，以每 股供股股份1.00港元的认购价进行供股，借 ...